Regonol

Active Ingredient(s): Pyridostigmine
FDA Approved: * August 14, 1973
Pharm Company: * SANDOZ
Category: Myasthenic Syndrome

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Regonol Overview

Pyridostigmine is a medication used to treat myasthenia gravis.[1] It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type.[2] It is typically given by mouth but can also be used by injection.[2] The effects generally begin within 45 minutes and last up to 6 hours.[2] Common side effects include nausea, diarrhea, frequent urination, and abdominal pain.[2&...

Read more Regonol Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pyridostigmine

Recent Regonol Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pyridostigmine
  • Injection: 5mg/ml
  • Syrup: 60mg/5ml
  • Tablet: 60mg
  • Tablet, Extended Release: 180mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Regonol: (1 result)

Sorted by National Drug Code
  • 0781-3040 Regonol 5 mg/ml Intravenous; Parenteral Injection, Solution by Sandoz Inc

Other drugs which contain Pyridostigmine or a similar ingredient: (2 results)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA